(Q42926976)

11 November 2017

title

Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies (English)

1 reference

11 November 2017

2

Alexander Thielen

0 references

author name string

Theresa Mo

3

1 reference

11 November 2017

Winnie Dong

4

1 reference

11 November 2017

Douglass Chapman

6

1 reference

11 November 2017

Marilyn Lewis

7

1 reference

11 November 2017

Ian James

8

1 reference

11 November 2017

Jayvant Heera

9

1 reference

11 November 2017

Hernan Valdez

10

1 reference

11 November 2017

Rachel A. McGovern

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20736814

22 June 2024

Conan K. Woods

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20736814

22 June 2024

P. Richard Harrigan

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20736814

22 June 2024

language of work or name

English

0 references

publication date

1 October 2010

1 reference

11 November 2017

23 October 2010

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20736814

full work available at URL

22 June 2024

http://journals.lww.com/00002030-201010230-00011

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

22 June 2024

1 reference

11 November 2017

volume

24

1 reference

11 November 2017

issue

16

1 reference

11 November 2017

page(s)

2517-2525

1 reference

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

11 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

Maraviroc for previously treated patients with R5 HIV-1 infection

22 June 2024

2

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection

22 June 2024

3

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

22 June 2024

4

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211

22 June 2024

5

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

Maraviroc: integration of a new antiretroviral drug class into clinical practice

22 June 2024

6

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

22 June 2024

7

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

Trofile HIV co-receptor usage assay.

22 June 2024

8

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.

22 June 2024

9

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism

22 June 2024

10

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism

22 June 2024

12

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule

22 June 2024

13

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART

22 June 2024

14

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences

22 June 2024

15

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates.

22 June 2024

16

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists.

22 June 2024

17

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211

22 June 2024

18

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E6CFB

22 June 2024

Identifiers

1 reference

11 November 2017

1 reference